North Carolina achieved a record-breaking year for life sciences investments in 2024. Twenty-five companies announced ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Novo-Nordisk AS (Symbol: NVO) entered into oversold territory, hitting an RSI reading of 28 ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks Jim Cramer recently discussed. In a recent episode of CNBC’s Squawk On The ...

Novo Nordisk is a multinational corporation with facilities across the globe, including six in the U.S. The company has a facility in Clayton, N.C., where it fills and packages most injectable ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” to continue to benefit from the high demand for ...

Novo Nordisk already has quite the presence in Clayton. The company’s first facility in Clayton became operational in 1996. It later added a second facility in Clayton for the production of ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for legal issues in China. One of these stocks has a stronger investment ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.

To hear Novo tell it, the outsourcing group OFA shouldn’t be allowed to place liraglutide on its compounding list given that FDA-approved generics to Victoza are available. Further, the OFA has ...

The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and ...